Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @AdAlta1AD
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AdAlta1AD
-
More evidence of big pharma interest in
#Fibrosis with Boehringer Ingelheim and Enleofen announcing a $US1bn + deal for fibro-inflammatory diseases. Our i-body based therapeutic, AD-214 is due to enter the clinic in 2020. http://bit.ly/2tGnx1E $1AD#IPFHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thanks
@StockheadAU for the great coverage of our#BiomedicalTranslationBridge grant. The funding is to develop and clinically evaluate a radio-labelled version of AD-214 for imaging of the cell surface receptor CXCR4 in#IPF patients. More here: https://bit.ly/34azPvG $1ADHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Delighted to announce
@AdAlta1AD has been awarded A$1m in funding from Medical Research Future Fund’s#BiomedicalTranslationBridge program to develop an imaging agent for our lead#IPF therapeutic, AD-214. More: http://bit.ly/2E5Ukz7 $1ADHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
More evidence of big pharma interest in Idiopathic Pulmonary
#Fibrosis with Roche's ~USD 1.39b acquisition of fibrosis-focused Promedior announced Friday. Our i-body based therapeutic, AD-214 is due to enter the clinic in 2020. https://bit.ly/32Q6ZQE $1AD#IPFHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@AdAlta1AD Chief Scientific Officer Mick Foley chairing AusBiotech Panel Discussion showing the strength of Australian biotech, "Anti-fibrotic drugs: A hot area for big pharma" with@dimerixltd@Pharmaxis@certatx_aupic.twitter.com/R4J9adx5Wd
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
As well as the good results from our non-human primate study, we’re pleased to announce that the GMP manufacturing of AD-214 for our phase 1 human study is now complete. $1AD Read the announcement here: http://1ad.live.irmau.com/irm/PDF/1596_0/GLPToxicologystudyresults …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Pleased to announce we’ve completed our non-human primate study necessary to take our lead candidate, AD-214, into human clinical trials. The study showed AD-214 was safe and well-tolerated with no mortalities or adverse events. Read the announcement here: http://1ad.live.irmau.com/irm/PDF/1597_0/GLPToxicologystudyresults …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
AdAlta Limited proslijedio/la je Tweet
New CEO of
@AdAlta1AD, Dr Tim Oldham speaks about the company’s business development strategy of developing in-house assets to key inflection points and working in partnership with big Pharma / biotech to develop drugs of commercial interest to them. $1AD#fibrosis#drugdiscoverypic.twitter.com/rDOW1ghoL5
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
AdAlta Limited proslijedio/la je Tweet
Chairman of
@AdAlta1AD, Paul MacLeman introduces the company and new CEO/MD, Dr Tim Oldham to investors at the 10th Annual Australian Microcap Conference. See the presentation here http://1ad.live.irmau.com/irm/PDF/1593_0/InvestorPresentationforAustralianMicrocapConference … $1AD#fibrosis#nextgenantibodiespic.twitter.com/cdf0WvE9b7
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Great to have the appointment of CEO Dr Tim Oldham covered in this week's
@BiotechDispatch $1AD#biologics#drugdevelopment#IPFhttps://biotechdispatch.com.au/news/industry-executive-to-lead-emerging-australian-biopharma-adalta …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dr Tim Oldham appointed as
@AdAlta1AD's new CEO and MD. Dr Oldham has extensive expertise in portfolio building, biologic development and pipeline commercialisation. He starts with us Monday 14 Oct. Read more: http://tiny.cc/tiz6dz $1AD#biologics#drugdevelopment#IPFHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
AdAlta Limited proslijedio/la je Tweet
Looking forward to seeing
@AnataraANR and@AdAlta1AD presenting at this year’s microcap conference!$ANR $1ADhttps://twitter.com/AusMicrocap/status/1181298413738037251 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Watch our Executive Chairman, Paul MacLeman talk with Finance News Network about our deal with
@GEHealthcare to develop i-bodies for diagnostic imaging. Read the full announcement here: http://tiny.cc/x90pcz#ibodies#diagnostics#imaging $1ADhttp://ow.ly/463Y30pxvIRHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are delighted to sign an agreement for our
#ibody platform with global medical technology firm, GE Healthcare. The licensing deal will see us develop i-bodies for diagnostic imaging. Read full announcement here: http://tiny.cc/x90pcz#ibodies#diagnostics#imaging $1ADHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Excited to see interest growing in the
#GPCR target space with the partnership between@soseiheptaresco and@TakedaPharma - great news for everyone involved in this sector#antibody#biotech#pharmahttps://www.fiercebiotech.com/biotech/takeda-sosei-form-gastrointestinal-disease-r-d-pact …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Fun Fact 3
@ir_department: we will be in the clinic with our first i-body AD-214 for the treatment of IPF.https://twitter.com/ir_department/status/1157172528588058629 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
AdAlta Limited proslijedio/la je Tweet
This is a wobbegong shark. Fun fact 1: wobbegong sharks do not have to keep on moving in order for them to breathe. Fun fact 2: Their antibodies inspired i-bodies that @AdAltaCEO now produces.
#SharkWeekpic.twitter.com/n2vIFW9TGD
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Excited to see another early stage
#IPF deal today. Boehringer has licensed Bridge Biotherapeutics’ IPF med for: EU45m upfront and EU1.1B in milestone payments. AdAlta enters the clinic in January with its#IPF candidate,#AD214.#fibrosishttps://twitter.com/FierceBiotech/status/1151867520896458753 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
“Scarred for life”
@AusBiotech case study profiles $1AD lead drug AD-214 for IPF#fibrosis#investment#biotech -http://bit.ly/2N8OfJqHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
AdAlta's i-body AD-214 featured in
@NatRevDrugDisc "Nanobody approval gives domain antibodies a boost"https://www.nature.com/articles/d41573-019-00104-w …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.